USD 550 million awarded in lawsuit linking cancer, baby powder

R St Louis (US): Nearly two dozen women who claimed asbestos in Johnson & Johnson talcum powder caused their ovarian cancer were awarded USD 550 million in damages by a St Louis jury in the first case against the company that focused on asbestos in the powder.

Punitive damages are still to be decided for the 22 plaintiffs in a case that began June 4 in St Louis Circuit Court.

Plaintiffs’ lawyer Mark Lanier told the jurors during closing arguments on Wednesday that this case was the first where jurors saw documents showing that Johnson & Johnson knew its products contained asbestos and didn’t warn consumers, The St. Louis Post-Dispatch reported .

“Your voice is not just the voice of the community but the voice of the world,” Lanier said. “You don’t jack with people’s lives like this. … It’s just not right.”

Johnson & Johnson spokeswoman Carol Goodrich said in a statement that the company was disappointed with yesterday’s verdict but would not comment further until the punitive damages are announced.

The company has been sued by more than 9,000 women who claim its talcum powder contributed to their ovarian cancer. Johnson & Johnson has consistently denied that its products can be linked to the cancer.

Five previous cases have been decided and Johnson & Johnson has appealed those that it lost.

During closing arguments, Johnson & Johnson lawyer Peter Bicks said the company for years has exceeded industry standards in testing talcum powder for asbestos and cited several scientific studies and conclusions by US government agencies that he said found the company’s products didn’t contain asbestos and were safe.

“Yes, this is terrible,” Bicks said of the women’s cancer. “But just because something terrible happened doesn’t mean Johnson & Johnson had anything to do with it.” Six of the 22 plaintiffs in the latest trial have died from ovarian cancer. Five plaintiffs were from Missouri, with others from states that include Arizona, New York, North Dakota, California, Georgia, the Carolinas and Texas.

One of the plaintiffs, Gail Ingham, 73, of O’Fallon, Missouri, told The Post-Dispatch that she was diagnosed with stage-3 ovarian cancer in 1985 and underwent chemotherapy treatments, surgeries and drug treatments for a year before being declared cancer free in the early 1990s.

Ingham, who used baby powder for decades, said she joined the lawsuit because women who use baby powder “need to know what’s in there. They need to know what’s going on. Women need to know because they’re putting it on their babies.” (AP) HMB

  • Related Posts

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Phase 2 results for LB-102 showed statistically significant reductions in PANSS total score across all doses with onset by week 1 and sustained through study end, alongside low rates of…

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    After substandard drug manufacturing, the state drug firms are once again under the scanner of the central government for manufacture and sale of unapproved fixed dose combination (FDC) drugs which…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise